SEARCH RESULTS

2 RESULTS

Kasper Kepp on Biogen/Eisai Halt Phase 3 Aducanumab Trials

COMMENT It was no surprise to me in the field that aducanumab would fail. The reasons are predicted and well-described, for example in the papers listed below. It has been known for many years that the amyloid hypothesis cannot be correct; the reason it survives ...

Current Filters

  • TYPE: Comment x
  • Commentator: Kepp, Kasper x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE